CareDx : Corporate Presentation March 2022

The Transplant Company™

Focused on improving care across the entire transplant patient journey

Leslie M, Kidney Transplant Recipient

Corporate Presentation:

March 2022

Safe Harbor Statement

These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the future financial position of CareDx, Inc. (together with its subsidiaries, "CareDx" or the "Company"), including financial targets, business strategy, and plans and objectives for future operations, are forward-looking statements. CareDx has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. These

forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the "Risk Factors" section of

the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission (the "SEC"). In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. CareDx undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this presentation or to conform these statements to actual results or to changes in CareDx's expectations.

These slides and the accompanying oral presentation contain certain non-GAAP financial measures, which are provided to assist in an understanding of the business and performance of CareDx. These measures should always be considered only as a supplement to, and not as superior to, financial measures prepared in accordance with GAAP. Please refer to the Appendix included in these slides for a reconciliation of the non-GAAP financial measures included in these slides and the accompanying oral presentation to the most directly comparable financial measures prepared in accordance with GAAP.

Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.

2

Our Vision

The leading partner for the transplant ecosystem

Our Mission

We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey

Building Multiple Businesses in Attractive Transplant TAM

Long-Term Plan

Build Pharma Partner Business

With AlloSeq, AlloCell, AlloHeme…

Establish the Digital Business

AlloCare, MedActionPlan, OTTR, XYN-QAPI,XYN-WLM, TransChart, Tx Access, TxHero

Expand Testing Products Business

AlloSeq (cfDNA, Tx17, HCT) franchise

Grow Testing Services Business

$4B+ (Kidney, Heart), $1B (Liver, Lung)

$12B+ TAM*

~$5B+

TAM*

~$1B+

TAM*

~$1B+

TAM*

~$5B+

TAM*

* Market sizing based on CareDx internal analysis	4

Vision: The Leading Partner Across Transplant

Example: US Centers

HEART	KIDNEY	LUNG

Deep Center	90%+	70%+	40%
Penetration	Centers Using AlloMap	Centers Using AlloSure	Centers Using AlloSure Lung

Clinical	60+	70+	15+
Partnerships	SHORE Centers	KOAR/OKRA Centers	ALAMO Centers/
Investigator Initiated Trials

								Leadership	> 1 in 2	1 in 3	~700
								Indicators	Newly Transplanted Patients	Newly Transplanted Patients	Tests in First Quarter of Launch

Note: Center penetration based on UNOS listed transplant centers as of Q1 2021; does not include non-transplant hospitals.

5